open access

Vol 77, No 2 (2009)
EDUKACJA. Zmniejszmy ciężar przewlekłej obturacyjnej choroby płuc (cz. II)
Published online: 2009-03-16
Submitted: 2013-02-22
Get Citation

Role of inhaled corticosteroids in the management of COPD

Ryszarda Chazan
Pneumonol Alergol Pol 2009;77(2):186-191.

open access

Vol 77, No 2 (2009)
EDUKACJA. Zmniejszmy ciężar przewlekłej obturacyjnej choroby płuc (cz. II)
Published online: 2009-03-16
Submitted: 2013-02-22

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Role of inhaled corticosteroids in the management of COPD

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 2 (2009)

Pages

186-191

Published online

2009-03-16

Bibliographic record

Pneumonol Alergol Pol 2009;77(2):186-191.

Authors

Ryszarda Chazan

References (33)
  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the diagnosis, management and prevention of chronic obstructive lung disease. http://www.goldcopd.org.
  2. Tashkin D, Celli B, Decramer M, et al. Prescribing patterns according to COPD treatment guidelines in patients enrolled in a global clinical trial. PATS. 2006; 3: abstract.
  3. Miravitlles M, Brosa M, Velasco M, et al. An economic analysis of pharmacological treatment of COPD in Spain. Respir Med. 2009; 103(5): 714–721.
  4. Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008; 24(11): 3063–3072.
  5. Celli B, Decramer M, Kesten S, et al. UPLIFT Study Investigators, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543–1554.
  6. Profita M, Giorgi RDi, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005; 60(11): 1361–1369.
  7. Bühling F, Lieder N, Kühlmann UC, et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med. 2007; 101(11): 2386–2394.
  8. Iesato K, Tatsumi K, Saito K, et al. Tiotropium bromide attenuates respiratory syncytial virus replication in epithelial cells. Respiration. 2008; 76(4): 434–441.
  9. Pahl A, Bauhoffer A, Petzold U, et al. Synergistic effect of the anticholinergic R, R-glycopyrrolate with antiinflammatory drug. Bioch Pharm. 2006; 72: 169–172.
  10. Roig J, Hernando R, Mora R. Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist. Open Respir Med J. 2009; 3: 27–30.
  11. Singh D, Fiebich K, Dederichs J. Dose delivery characterization of indacaterol following inhalation by COPD patients. Am. J. Respir. Crit Care Med. 2010; 181: A4419.
  12. Kornmann O, Dahl R, Centanni S, et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37(2): 273–279.
  13. Dahl R, Chung KF, Buhl R, et al. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65(6): 473–479.
  14. Donohue JF, Fogarty C, Lötvall J, et al. INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182(2): 155–162.
  15. Donohue JF, Decramer MD, Owen R, et al. Indacaterol provides significant bronchodilatation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use. . Am. J. Respir. Crit. Care Med. 2010; 181: A4438.
  16. Siler TN, Williams J, Yegen U. The effect of once-daily indacaterol on health-related quality of life rescue medication use and exacerbation rates in patients with moderate to severe COPD: a pooled analysis of three months of treatment. Am. J. Respir. Crit. Care Med. 2010; 181: A4430.
  17. Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol. 2008; 121(3): 580–584.
  18. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive lung disease. N Engl J Med. 2005; 25: 552–563.
  19. Mapel D, Hurley J, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respiratory Medicine. 2006; 100(4): 595–609.
  20. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008; 155(3): 291–299.
  21. Bhavsar PK, Khorasani NJ. Improvement in corticosteroid sensitivity in PBMCs from patients with COPD by p38MAPK inhibition. Am. J. Respir. Crit. Care Med. 2009; 179: A6187.
  22. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009; 179(7): 542–548.
  23. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest. 2008; 134(2): 394–401.
  24. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010; 23(4): 235–256.
  25. Rabe KF. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2010; 4(5): 543–555.
  26. Press NJ, Banner KH. PDE4 inhibitors - a review of the current field. Prog Med Chem. 2009; 47: 37–74.
  27. Calverley PMA, Rabe KF, Goehring UM, et al. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691): 685–694.
  28. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691): 695–703.
  29. Rabe KF. Treating COPD--the TORCH trial, P values, and the Dodo. N Engl J Med. 2007; 356(8): 851–854.
  30. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007; 132(6): 1764–1771.
  31. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008; 62(9): 1373–1378.
  32. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29(2): 279–283.
  33. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol. 2005; 45: 89–118.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl